Skip to main content

Table 1 Clinical profile of patients with B-cell lymphoma of the mediastinum

From: Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma

  

CHL, NS (N = 13)

PMLBCL (N = 16)

p value

Gray zone (N = 3)

Age

Median (Range)

26(15–73)

30 (19–51)

0.175

28 (25–52)

Sex

Male: Female

4(30.8%): 9(69.2%)

6(37.5%): 10(62.5%)

1.000

2: 1

Methods of biopsy

Needle: VATS: Open

6: 3: 4

10: 4: 2

 

0: 0: 3

IPI score

High risk (> 3) or low

7(87.5%): 1(12.5%)

13(86.7%): 2(13.3%)

1.000

1: 2

Ann Arbor stage

I-II: III-IV

8(80.0%): 2(20.0%)

10(71.4%): 4(28.5%)

1.000

1: 2

LDH

Elevated or not

4(57.1%): 3(42.9%)

12(80.0%): 3(20.0%)

0.334

0: 3

ECOG score

≥2 or less

0: 12(100%)

0: 14(100%)

 

0: 3

Bone marrow

Involved or not

1(9.1%): 10(90.9%)

2(13.3%): 13(86.7%)

1.000

0: 3

Bulky disease

Yes or No

6(54.5%): 5(45.5%)

11(73.3%): 4(26.7%)

0.419

1: 2

B symptoms

Yes or No

5(55.6%): 4(44.4%)

4(28.6%): 10(71.4%)

0.383

1: 2

Follow-up (months)

Median (Range)

72 (1–116)

14(1–57)

 

48 (14–84)

 

Dead/Alive

0: 12(100%)

4(26.7%): 11(73.3%)

0.106

1: 2

Progression

Yes or No

0: 12(100%)

6(42.9%): 8(57.1%)

0.017

1: 2

  1. CHL classic Hodgkin lymphoma, NS nodular sclerosis, PMLBCL primary mediastinal diffuse large B-cell lymphoma (DLBCL); Gray, B-cell lymphoma unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma; VATS video-assisted thoracoscopic surgery